Jefferies Downgrades Esperion Therapeutics (ESPR) to Hold, PT to $3.28
Tweet Send to a Friend
Jefferies analyst Dennis Ding downgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Hold with a price target of $3.28 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
